These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 24188261

  • 1. Management of patients with castration-resistant disease.
    Pezaro C, Omlin A, Lorente D, de Bono J.
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1243-60, ix. PubMed ID: 24188261
    [Abstract] [Full Text] [Related]

  • 2. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR, Hussain MH.
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [Abstract] [Full Text] [Related]

  • 3. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H, Garcia JA.
    Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
    [Abstract] [Full Text] [Related]

  • 4. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients.
    Attard G, de Bono JS.
    Clin Cancer Res; 2011 Jun 15; 17(12):3867-75. PubMed ID: 21680542
    [Abstract] [Full Text] [Related]

  • 5. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).
    Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, Shariat SF.
    BJU Int; 2012 Apr 15; 109(7):968-85. PubMed ID: 22035221
    [Abstract] [Full Text] [Related]

  • 6. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.
    Eur Urol; 2011 Aug 15; 60(2):279-90. PubMed ID: 21592649
    [Abstract] [Full Text] [Related]

  • 7. [The treatment of castration-resistant prostate cancer].
    Petrányi Á.
    Magy Onkol; 2012 Dec 15; 56(4):219-28. PubMed ID: 23236591
    [Abstract] [Full Text] [Related]

  • 8. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
    Tsao CK, Galsky MD, Small AC, Yee T, Oh WK.
    BJU Int; 2012 Dec 15; 110(11):1580-8. PubMed ID: 22985411
    [Abstract] [Full Text] [Related]

  • 9. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA, Dzik C, Rathkopf D, Scher HI.
    Oncology (Williston Park); 2014 Aug 15; 28(8):693-9. PubMed ID: 25140626
    [Abstract] [Full Text] [Related]

  • 10. Targeting continued androgen receptor signaling in prostate cancer.
    Massard C, Fizazi K.
    Clin Cancer Res; 2011 Jun 15; 17(12):3876-83. PubMed ID: 21680543
    [Abstract] [Full Text] [Related]

  • 11. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
    Mitsiades N.
    Cancer Res; 2013 Aug 01; 73(15):4599-605. PubMed ID: 23887973
    [Abstract] [Full Text] [Related]

  • 12. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.
    Eur Urol; 2014 Feb 01; 65(2):289-99. PubMed ID: 23957948
    [Abstract] [Full Text] [Related]

  • 13. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N.
    Expert Opin Investig Drugs; 2010 Jul 01; 19(7):837-46. PubMed ID: 20524793
    [Abstract] [Full Text] [Related]

  • 14. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D, De Bono JS.
    Eur J Cancer; 2014 Mar 01; 50(4):753-64. PubMed ID: 24418724
    [Abstract] [Full Text] [Related]

  • 15. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
    Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.
    Eur J Cancer; 2014 Jun 01; 50(9):1617-27. PubMed ID: 24703899
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Castrate-resistant prostate cancer: postdocetaxel management.
    Zhao S, Yu EY.
    Curr Opin Urol; 2013 May 01; 23(3):201-7. PubMed ID: 23344012
    [Abstract] [Full Text] [Related]

  • 19. Novel chemotherapies in development for management of castration-resistant prostate cancer.
    Tewari AK, George DJ.
    Curr Opin Urol; 2013 May 01; 23(3):220-9. PubMed ID: 23511791
    [Abstract] [Full Text] [Related]

  • 20. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.
    Actas Urol Esp; 2011 May 01; 35(10):565-79. PubMed ID: 21757258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.